KBC Group’s Verve Therapeutics VERV Stock Holding History

KBC Group’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,750	Closed	-$23K	–	1916
2024 Q1	$23K	Buy	+1,750	New	+$23.2K	﹤0.01%	1820

Other funds holding VERV

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

KBC Group's VERV Position: Q2 2024 in Review

KBC Group sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 1,750 shares — an estimated $23K sold.

KBC Group first reported a position in VERV in Q1 2024 and held it in 1 quarter. The position peaked at $23K in Q1 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

KBC Group reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
KBC Group sold 1,750 Verve Therapeutics shares in Q2 2024, an estimated $23K.
KBC Group first reported a position in Verve Therapeutics in Q1 2024 and held it in 1 quarter.
KBC Group's Verve Therapeutics position peaked at $23K in Q1 2024.
166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on KBC Group's 13F filing for Q2 2024, filed 17 Jul 2024.